State of the Science Summit on Genitourinary Cancers | Conference

Assessing Long-Anticipated Treatment Advances in Metastatic Urothelial Cancer

January 2nd 2020

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

Dr. Barocas on the CEASAR Trial in Localized Prostate Cancer

December 4th 2019

Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.

Dr. Beckermann on Sequencing Strategies in mRCC

December 4th 2019

Kathryn E. Beckermann, MD, PhD, instructor of medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses sequencing strategies in metastatic renal cell carcinoma (mRCC).

Expert Shares Insight on Recent Prostate Cancer Developments

November 27th 2019

Sam S. Chang, MD, discusses the utility of genetic testing in prostate cancer and pivotal research efforts.

Dr. Shinohara on Stereotactic Body Radiotherapy to Treat Prostate Cancer

November 26th 2019

Eric Shinohara, MD, MSCI, discusses the emergence of stereotactic body radiotherapy to treat patients with prostate cancer.

Dr. Penson on Treatment Selection in Metastatic Hormone-Sensitive Prostate Cancer

November 22nd 2019

David F. Penson, MD, MPH, MMHC, discusses treatment selection in patients with metastatic hormone-sensitive prostate cancer.

Dr. Chang on the Use of PARP Inhibitors in Prostate Cancer

November 20th 2019

Sam S. Chang, MD, MBA, discusses the shift toward personalized therapy in prostate cancer.

Selecting Among AR-Directed Agents in Nonmetastatic CRPC

November 16th 2019

David Morris, MD, FACS, provides an update on the 3 newest agents available for nonmetastatic castration-resistant prostate cancer treatment and discussed factors to consider when choosing among them.

Dr. Sonpavde on Immunotherapy After Progression in Advanced Bladder Cancer

September 10th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the use of immunotherapy after progression on platinum-based therapy in advanced bladder cancer.

Tracers Increase PET Imaging Sensitivity in Prostate Cancer

August 27th 2019

Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.

Research Initiative Comparing Proton Therapy With IMRT in Prostate Cancer

August 27th 2019

Randal Henderson, MD, MBA, discusses the data that led to the PCORI-funded trial, what the results could mean for the field, and interesting research on the horizon.

Precision Medicine to Take Hold in Advanced Bladder Cancer

August 26th 2019

Parminder Singh, MD, discusses ongoing research in advanced urothelial cancer and the focus on incorporating precision medicine in the field.

Armamentarium Continues to Evolve Across Metastatic Prostate Cancer

August 26th 2019

Manish Kohli, MD, discusses the agents that have redefined the treatment paradigm of metastatic prostate cancer and details ongoing work to elucidate genomic classifiers.

Dr. Joseph on the Combination of Atezolizumab and Bevacizumab in mRCC

August 23rd 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in metastatic renal cell carcinoma (mRCC).

Dr. Henderson on Proton Therapy Versus IMRT in Prostate Cancer

August 22nd 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology and associate medical director at the University of Florida Health Proton Therapy Institute, discusses the potential benefits of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

Clearing Up Confusion on Cytoreductive Nephrectomy in mRCC

August 20th 2019

David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.

Dr. Jain on the Indications for PET Imaging in Prostate Cancer

August 20th 2019

Manoj K. Jain, MD, nuclear medicine specialist, radiologist, Mayo Clinic, discusses the indications for PET imaging in prostate cancer.

Dr. Henderson on the Benefits of Proton Therapy in Prostate Cancer

August 16th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses the benefits of proton therapy in prostate cancer.

Dr. Thiel on Surgical Advances for RCC

August 15th 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the advancements in surgical techniques for renal cell carcinoma.

Dr. Tan on Imaging Modalities in Prostate Cancer

August 15th 2019

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.